Literature DB >> 6732226

Single-dose pharmacokinetics of cefsulodin in patients with cystic fibrosis.

M D Reed, R C Stern, T S Yamashita, I Ackers, C M Myers, J L Blumer.   

Abstract

The single-dose pharmacokinetics of cefsulodin were evaluated in 12 patients with cystic fibrosis. Each patient received 3 g of cefsulodin intravenously over 30 min. Multiple plasma and urine samples were obtained during the 6-h study period for the determination of cefsulodin. Pharmacokinetic parameters were determined by model-independent methods. Mean values for t1/2, Vss, and CLp were 1.53 h, 0.242 liters/kg, and 117.3 ml/min per 1.73 m2, respectively. Six-hour urine recovery revealed 73.2% of the administered dose with a corresponding cefsulodin urinary clearance of 75.1 ml/min. These pharmacokinetic data in patients with cystic fibrosis appear consistent with data reported for unaffected individuals.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6732226      PMCID: PMC185590          DOI: 10.1128/AAC.25.5.579

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Comparative in vivo activities of cefsulodin, sulbenicillin, and gentamicin against Pseudomonas aeruginosa.

Authors:  M Kondo; K Tsuchiya
Journal:  Antimicrob Agents Chemother       Date:  1978-07       Impact factor: 5.191

2.  Difference in renal handling of cefsulodin between patients with cystic fibrosis and normal subjects.

Authors:  A Arvidsson; G Alván; B Strandvik
Journal:  Acta Paediatr Scand       Date:  1983-03

3.  Pharmacokinetics of tobramycin in cystic fibrosis.

Authors:  H B Kelly; R Menendez; L Fan; S Murphy
Journal:  J Pediatr       Date:  1982-02       Impact factor: 4.406

4.  Pharmacokinetic concepts - drug binding, apparent volume of distribution and clearance.

Authors:  M Gibaldi; J R Koup
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Precise high-performance liquid chromatographic procedure for the determination of cefsulodin, a new antipseudomonal cephalosporin antibiotic, in plasma.

Authors:  G R Granneman; L T Sennello
Journal:  J Pharm Sci       Date:  1982-10       Impact factor: 3.534

6.  Pharmacokinetics of methicillin in patients with cystic fibrosis.

Authors:  S J Yaffe; L M Gerbracht; L L Mosovich; M E Mattar; M Danish; W J Jusko
Journal:  J Infect Dis       Date:  1977-05       Impact factor: 5.226

7.  Cefsulodin pharmacokinetics in patients with various degrees of renal function.

Authors:  G R Matzke; W F Keane
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

8.  Cefsulodin kinetics in renal impairment.

Authors:  T P Gibson; G R Granneman; J E Kallal; L T Sennello
Journal:  Clin Pharmacol Ther       Date:  1982-05       Impact factor: 6.875

9.  Cefsulodin kinetics in healthy subjects after intramuscular and intravenous injection.

Authors:  G R Granneman; L T Sennello; R C Sonders; B Wynne; E W Thomas
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

10.  Dosing implications of altered gentamicin disposition in patients with cystic fibrosis.

Authors:  G L Kearns; B C Hilman; J T Wilson
Journal:  J Pediatr       Date:  1982-02       Impact factor: 4.406

View more
  8 in total

1.  Increased renal clearance of cefsulodin due to higher glomerular filtration rate in cystic fibrosis.

Authors:  A Hedman; G Alván; B Strandvik; A Arvidsson
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 2.  Clinical pharmacology of antibiotics and other drugs in cystic fibrosis.

Authors:  J Prandota
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

Review 3.  High dose treatment with antibiotics in cystic fibrosis--a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients.

Authors:  F Sörgel; U Stephan; H G Wiesemann; B Gottschalk; C Stehr; M Rey; H B Böwing; H C Dominick; M Geldmacher von Mallinckrodt
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 4.  Pharmacokinetics of antibiotics in cystic fibrosis patients with particular reference to the bronchopulmonary tree (review).

Authors:  E Bergogne-Berezin
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

Review 5.  Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance.

Authors:  R de Groot; A L Smith
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

Review 6.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

7.  Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis.

Authors:  M D Reed; R C Stern; C A O'Brien; T S Yamashita; C M Myers; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

8.  Ciprofloxacin pharmacokinetics in patients with cystic fibrosis.

Authors:  S W Bender; A Dalhoff; P M Shah; R Strehl; H G Posselt
Journal:  Infection       Date:  1986 Jan-Feb       Impact factor: 3.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.